

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/235610 A9

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(51) International Patent Classification:

A61K 35/34 (2015.01) A61P 9/06 (2006.01)
A61K 35/545 (2015.01) C12N 5/07 (2010.01)
A61P 9/00 (2006.01)

(21) International Application Number:

PCT/US2022/027382

(22) International Filing Date:

03 May 2022 (03.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/183,528 03 May 2021 (03.05.2021) US
63/211,843 17 June 2021 (17.06.2021) US
63/292,046 21 December 2021 (21.12.2021) US

(71) Applicant: UNIVERSITY OF WASHINGTON

[US/US]; 4545 Roosevelt Way NE, Suite 400, Seattle,
Washington 98105 (US).

(72) Inventors: MURRY, Charles E.; c/o University of Washington, 4545 Roosevelt Way NE, Suite 400, Seattle, Wash-

ington 98105 (US). **MARCHIANO, Silvia**; c/o University of Washington, 4545 Roosevelt Way NE, Suite 400, Seattle, Washington 98105 (US). **REINECKE, Hans**; c/o University of Washington, 4545 Roosevelt Way NE, Suite 400, Seattle, Washington 98105 (US). **BERTERO, Alessandro**; c/o University of Washington, 4545 Roosevelt Way NE, Suite 400, Seattle, Washington 98105 (US).

(74) Agent: FITZGERALD, Mark J. et al.; Nixon Peabody LLP, Exchange Place, 53 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: ELECTROPHYSIOLOGICAL MODIFICATION TO SUPPRESS ARRHYTHMIAS




FIG. 1C

(57) Abstract: Described herein are compositions and methods related to the treatment of a cardiovascular disease or disorder. Also described herein are cells, stem cells (including embryonic and pluripotent stem cells), and *in vitro*-differentiated human cardiomyocytes in which HCN4 (*HCN4*), Cav3.2 (*CACNA1H*) and NCX1 (*SLC8A1*) activities are at least partially inhibited, and Kir2.1 (*KCNJ2*) activity is at least partially stimulated in such cells. Also described herein are formulations for the delivery of such cells and methods of transplanting cardiomyocytes, e.g., for the treatment or prevention of a disease or disorder.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

06 April 2023 (06.04.2023)

(15) Information about Correction:

see Notice of 06 April 2023 (06.04.2023)